search button

Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer

  • Authors:
    • Sheng-Liu Xue
    • Hua-Fang Su
    • Xiao-Qu Hu
    • Xia Deng
    • Mei-Long Hu
    • Cong-Ying Xie

  • View Affiliations

  • Published online on: September 13, 2012     https://doi.org/10.3892/ol.2012.914
  • Pages: 1309-1314
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The optimal adjuvant treatment modality for gastric cancer has not been well defined. The aim of this study was to evaluate the efficacy and feasibility of adjuvant combined systemic and intraperitoneal chemotherapy (ACSIP) in high-risk patients with locally advanced gastric cancer. Between June 2003 and December 2008, 62 eligible patients with serosa-infiltrating and/or node-positive gastric cancer following curative gastrectomy with D2 lymphadenectomy received ACSIP, consisting of intravenous oxaliplatin 85 mg/m2 on day 1 followed by leucovorin (LV) 200 mg/m2 and 5-fluorouracil (5-FU) 450 mg/m2 on days 1-3, intraperitoneal 5-FU 600 mg/m2 on days 4-5 and cisplatin (CDDP) 40 mg/m2 on day 5. Survival rates, the sites of first treatment failure and safety were analyzed. At a median follow-up of 45 months (range 7-101), the 3-year disease-free survival (DFS) and overall survival (OS) rates were 66.1 and 74.2%, respectively. Initial peritoneal and hepatic failures were found in 6 (24.0%) and 3 (12.0%) of the 25 patients with recurrence, respectively. Neutropenia, gastrointestinal side effects and peripheral neuropathy were the most common grade 3-4 toxicities; however, they were all infrequent and manageable. No serious surgical complications or treatment-related mortality was observed. The results of this study indicate that ACSIP is effective and feasible for locally advanced gastric cancer with encouraging survival rates and possibly decreased peritoneal and hepatic recurrences. The benefits of this promising combined adjuvant treatment modality warrant further studies.
View Figures
View References

Related Articles

Journal Cover

December 2012
Volume 4 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Xue S, Su H, Hu X, Deng X, Hu M and Xie C: Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer. Oncol Lett 4: 1309-1314, 2012.
APA
Xue, S., Su, H., Hu, X., Deng, X., Hu, M., & Xie, C. (2012). Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer. Oncology Letters, 4, 1309-1314. https://doi.org/10.3892/ol.2012.914
MLA
Xue, S., Su, H., Hu, X., Deng, X., Hu, M., Xie, C."Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer". Oncology Letters 4.6 (2012): 1309-1314.
Chicago
Xue, S., Su, H., Hu, X., Deng, X., Hu, M., Xie, C."Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer". Oncology Letters 4, no. 6 (2012): 1309-1314. https://doi.org/10.3892/ol.2012.914